Bajaj healthcare unveils Magnesium L-Threonate in nutraceutical segment

The product is available in 500 mg capsules for oral administration.

Published On 2022-02-25 07:42 GMT   |   Update On 2022-02-25 07:42 GMT

Thane: Bajaj Healthcare Limited, a manufacturer of APIs, Intermediates and Formulations, has announced that the company has launched Magnesium L-Threonate in Nutraceutical segment.Magnesium L- Threonate is a nutritional supplement used to normalize magnesium level in the body, helps to improve memory, muscle and nerve function and also aids in brain development by reversing the brain aging....

Login or Register to read the full article

Thane: Bajaj Healthcare Limited, a manufacturer of APIs, Intermediates and Formulations, has announced that the company has launched Magnesium L-Threonate in Nutraceutical segment.

Magnesium L- Threonate is a nutritional supplement used to normalize magnesium level in the body, helps to improve memory, muscle and nerve function and also aids in brain development by reversing the brain aging. It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, Attention disorder, Bipolar disorder, Parkinson's disease etc.

The advantages include that it is used to prevent the loss of synapses and to improve the cognitive functions of the brain. Magnesium L- Threonate increases the magnesium ion concentration in the brain better than Magnesium Sulphate. It helps to improve long term and short-term memory loss. It is useful in the formation of new nerve cells and synapses in brain and stimulates the neuronto-neuron communication. Magnesium L- Threonate readily crosses the blood brain barrier and support healthy magnesium level.
The product is available in 500 mg capsules for oral administration.
Commenting on the launch of Magnesium L-Threonate, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add Magnesium L-Threonate to our growing product portfolio and continue to carry through, Bajaj's commitment to deliver therapeutical products every year.
BHL intend to produce 12-15 tons of Magnesium L-Threonate in Q4 FY22 and 120 tons in FY23. We are expecting notable sales coming from the product. Addition of this new product in our existing product portfolio will further fuel the growth strategy for our formulation business. Addition of Magnesium LThreonate in our existing portfolio will further fuel the growth of our business and strengthen our position in the market."


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News